Literature DB >> 34791564

Treating Chronic Pain with Buprenorphine-The Practical Guide.

Amy A Case1, Justin Kullgren2, Sidra Anwar3, Sandra Pedraza4, Mellar P Davis5.   

Abstract

OPINION STATEMENT: Buprenorphine has unique and favorable pharmacological properties that make it useful in a variety of clinical scenarios. It has been recommended to consider buprenorphine first-line opioid for chronic pain, especially in the elderly as it may be associated with less cognitive impairment, falls, sexual dysfunction, and sarcopenia when compared with schedule II opioids. It may be useful in patients with comorbid substance use disorder or non-medical opioid use, as there is less risk of misuse, euphoria and it may improve mood. When used to treat opioid use disorder, the training and waiver was recently waived for licensed practitioners with a DEA and any provider may prescribe buprenorphine. For many reasons outlined in this article, the popularity of using buprenorphine for analgesia continues to grow and a practitioner should consider this as an excellent and safe option for chronic pain.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Buprenorphine; Chronic pain; Microdosing; Opioid

Mesh:

Substances:

Year:  2021        PMID: 34791564     DOI: 10.1007/s11864-021-00910-8

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  68 in total

Review 1.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

Review 3.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

4.  Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices.

Authors:  Mark Greenwald; Chris-Ellyn Johanson; Joshua Bueller; Yan Chang; David E Moody; Michael Kilbourn; Robert Koeppe; Jon-Kar Zubieta
Journal:  Biol Psychiatry       Date:  2006-09-01       Impact factor: 13.382

5.  Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases.

Authors:  Yan Chang; David E Moody
Journal:  Drug Metab Lett       Date:  2009-04

Review 6.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

7.  The metabolism and excretion of buprenorphine in humans.

Authors:  E J Cone; C W Gorodetzky; D Yousefnejad; W F Buchwald; R E Johnson
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

8.  Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016.

Authors:  James Dahlhamer; Jacqueline Lucas; Carla Zelaya; Richard Nahin; Sean Mackey; Lynn DeBar; Robert Kerns; Michael Von Korff; Linda Porter; Charles Helmick
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-09-14       Impact factor: 17.586

Review 9.  Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.

Authors:  Lynn Webster; Jeffrey Gudin; Robert B Raffa; Jay Kuchera; Richard Rauck; Jeffrey Fudin; Jeremy Adler; Theresa Mallick-Searle
Journal:  Pain Med       Date:  2020-04-01       Impact factor: 3.750

Review 10.  Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain.

Authors:  Joseph V Pergolizzi; Robert B Raffa
Journal:  J Pain Res       Date:  2019-12-13       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.